Biomedical subjects
Chetan Patel
Publications and source records attributed to Chetan Patel.
Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?
Cardiovascular disease is the most common complication of type 2 diabetes mellitus (type 2 DM), accounting for approximately 80% of deaths. While atherosclerotic vascular disease accounts for much of the cardiovascular morbidity and mortality among diabetic patients, congestive heart failure (CHF) is another key complication associated with diabetes, with an incidence three to five times greater in diabetic patients than in those without diabetes. One of the most promising developments in the treatment of type 2 DM has been the introduction of the thiazolidinedione (TZD) class of drugs, which appear to have pleiotropic effects beyond glycaemic control. Enthusiasm has been tempered, however, by concerns for safety in patients with CHF, given reports of worsening heart failure symptoms and peripheral oedema. With the growing epidemic of type 2 DM and the increasing use of TZDs, such concern has important therapeutic implications for a population of patients with a high prevalence of often subclinical systolic and diastolic dysfunction. This review provides an overview of the currently available data regarding the effects of TZDs on fluid retention and cardiac function. Particular emphasis is placed on the mechanisms of development of peripheral oedema and its significance in patients with impaired left ventricular function. TZDs are well known to cause an expansion in plasma volume; there has also been concern that TZDs may have direct toxic effects on the myocardium, leading to impaired cardiac function. Studies to date do not support this hypothesis and in fact there is growing evidence from animal models and human trials that treatment with TZDs actually improves cardiac function. There are also preclinical data to suggest TZDs may protect the myocardium in the setting of ischaemic insult or the toxic effects of myocardial lipid deposition. Ongoing clinical trials examining the use of these agents in patients at risk for heart failure will probably provide further insight into the aggregate cardiovascular effects of this promising class of medications.
Direct radionuclide cystography by supra-pubic puncture: comparison with conventional voiding cystourethrography.
BACKGROUND: Vesicoureteric reflux (VUR) and its complications are common problems encountered in paediatric practice. Voiding cystourethrography (VCU) is the primary investigation of choice. Direct radionuclide cystography (DRC) is utilized in the follow-up evaluation of children diagnosed with VUR. However, VCU and DRC both require catheterization, which children do not tolerate well. OBJECTIVE: In this prospective study we evaluated radionuclide cystography by direct supra-pubic puncture (SDRC) and instillation of the radiotracer into the bladder, avoiding catheterization. The results of this procedure were then compared with those of VCU. PATIENTS AND METHODS: A total of 43 children (eight females and 35 males; mean age, 5.73+/-3.28 years; range, 1.5-12 years) were studied. RESULTS: Out of the total 86 renal units, SDRC showed VUR in 22, whereas VCU showed VUR in 29. The SDRC and VCU results were concordant in 77 (90%) out of 86 renal units in the detection of VUR. The sensitivity, specificity, positive predictive value, and negative predictive value of SDRC when compared to VCU were 75.86%, 100%, 100% and 89%, respectively. The overall accuracy of SDRC was 91.86%. CONCLUSIONS: The supra-pubic direct radionuclide cystography is a simple technique for detecting as well as grading VUR. The technique avoids catheterization, is well tolerated by children and is without significant side effects.